Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) saw strong trading volume on Tuesday . 77,015 shares changed hands during mid-day trading, an increase of 16% from the previous session’s volume of 66,124 shares.The stock last traded at $2.31 and had previously closed at $2.29.

Several analysts have recently commented on the stock. FBR & Co reaffirmed a “buy” rating on shares of Conatus Pharmaceuticals in a report on Monday, April 18th. Brean Capital reiterated a “buy” rating and issued a $7.00 target price (down from $13.00) on shares of Conatus Pharmaceuticals in a research note on Monday, May 9th. Finally, Roth Capital assumed coverage on shares of Conatus Pharmaceuticals in a research note on Friday, July 1st. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. Conatus Pharmaceuticals has an average rating of “Buy” and a consensus price target of $9.66.

The firm has a 50-day moving average price of $2.15 and a 200-day moving average price of $2.19. The company’s market capitalization is $49.10 million.

Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings data on Thursday, May 5th. The biotechnology company reported ($0.35) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.35). During the same quarter last year, the firm posted ($0.38) EPS. On average, equities analysts predict that Conatus Pharmaceuticals Inc. will post ($1.53) EPS for the current fiscal year.

A hedge fund recently raised its stake in Conatus Pharmaceuticals stock. Jennison Associates increased its position in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) by 0.6% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 659,067 shares of the biotechnology company’s stock after buying an additional 3,983 shares during the period. Jennison Associates owned 3.32% of Conatus Pharmaceuticals worth $2,933,000 as of its most recent SEC filing.

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.